<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mimmun</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинская иммунология</journal-title><trans-title-group xml:lang="en"><trans-title>Medical Immunology (Russia)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1563-0625</issn><issn pub-type="epub">2313-741X</issn><publisher><publisher-name>SPb RAACI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15789/1563-0625-FOI-2321</article-id><article-id custom-type="elpub" pub-id-type="custom">mimmun-2321</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Особенности иммунного ответа  при фенотипах хронической обструктивной болезни легких</article-title><trans-title-group xml:lang="en"><trans-title>Features of immune response in different phenotypes of chronic obstructive pulmonary disease</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2492-3198</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Антонюк</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Antonyuk</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Д.м.н., профессор, заведующая лабораторией восстановительного лечения</p><p>г. Владивосток</p></bio><bio xml:lang="en"><p>PhD, MD (Medicine), Professor, Head, Rehabilitation Treatment Laboratory</p><p>Vladivostok</p></bio><email xlink:type="simple">antonyukm@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4286-2827</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Минеева</surname><given-names>Е. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Mineeva</surname><given-names>E. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>К.м.н., врач функциональной диагностики, врач-пульмонолог, научный сотрудник лаборатории восстановительного лечения</p><p>г. Владивосток</p></bio><bio xml:lang="en"><p>PhD (Medicine), Functional Diagnostics Doctor, Pulmonologist, Research Associate, Rehabilitation Treatment Laboratory</p><p>Vladivostok</p></bio><email xlink:type="simple">elmineeva@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9086-7369</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кнышова</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Knyshova</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>К.м.н., старший научный сотрудник лаборатории восстановительного лечения</p><p>690105, г. Владивосток, ул. Русская, 73г</p><p>Тел.: 8 (423) 278-82-01</p></bio><bio xml:lang="en"><p>PhD (Medicine), Senior Research Associate, Rehabilitation Treatment Laboratory</p><p>690105, Vladivostok, Russkaya str., 73g</p><p>Phone: 7 (423) 278-82-01</p></bio><email xlink:type="simple">v.knyshova@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0396-6380</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Юренко</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Urenko</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>К.м.н., младший научный сотрудник лаборатории восстановительного лечения</p><p>г. Владивосток</p></bio><bio xml:lang="en"><p>PhD (Medicine), Junior Research Associate, Rehabilitation Treatment Laboratory</p><p>Vladivostok</p></bio><email xlink:type="simple">yurenko_alla@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1009-9011</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Виткина</surname><given-names>Т. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Vitkina</surname><given-names>T. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Д.б.н., профессор РАН, ведущий научный сотрудник лаборатории биомедицинских исследований</p><p>г. Владивосток</p></bio><bio xml:lang="en"><p>PhD, MD (Biology), Professor, Russian Academy of Sciences, Leading Research Associate, Biomedical Research Laboratory</p><p>Vladivostok</p></bio><email xlink:type="simple">tash30@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Новгородцева</surname><given-names>Т. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Novgorodtseva</surname><given-names>T. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Д.б.н., профессор, главный научный сотрудник лаборатории биомедицинских исследований</p><p>г. Владивосток</p></bio><bio xml:lang="en"><p>PhD, MD (Biology), Professor, Chief Research Associate, Biomedical Research Laboratory</p><p>Vladivostok</p></bio><email xlink:type="simple">tatyana_novgorod@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6413-9840</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гвозденко</surname><given-names>Т. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Gvozdenko</surname><given-names>T. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Д.м.н., профессор РАН, главный научный сотрудник лаборатории восстановительного лечения</p><p>г. Владивосток</p></bio><bio xml:lang="en"><p>PhD, MD (Medicine), Professor, Russian Academy of Sciences, Chief Research Associate, Rehabilitation Treatment Laboratory</p><p>Vladivostok</p></bio><email xlink:type="simple">tagvozdenko@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Научно-исследовательский институт медицинской климатологии и восстановительного лечения – Владивостокский филиал ФГБНУ «Дальневосточный научный центр физиологии и патологии дыхания»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Research Institute of Medical Climatology and Rehabilitation Treatment, Far Eastern Scientific Center of Physiology and Pathology of Respiration</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>10</day><month>03</month><year>2022</year></pub-date><volume>24</volume><issue>1</issue><fpage>109</fpage><lpage>120</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Антонюк М.В., Минеева Е.Е., Кнышова В.В., Юренко А.В., Виткина Т.И., Новгородцева Т.П., Гвозденко Т.А., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Антонюк М.В., Минеева Е.Е., Кнышова В.В., Юренко А.В., Виткина Т.И., Новгородцева Т.П., Гвозденко Т.А.</copyright-holder><copyright-holder xml:lang="en">Antonyuk M.V., Mineeva E.E., Knyshova V.V., Urenko A.V., Vitkina T.I., Novgorodtseva T.P., Gvozdenko T.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.mimmun.ru/mimmun/article/view/2321">https://www.mimmun.ru/mimmun/article/view/2321</self-uri><abstract><p>Хроническую обструктивную болезнь легких (ХОБЛ) рассматривают как гетерогенное заболевание с различными фенотипами. Важным звеном в патогенезе ХОБЛ является хроническое системное воспаление. Изучение иммунного ответа в контексте клинико-функциональных фенотипов представляется актуальным. Цель исследования: изучить особенности иммунного ответа при клинико-функциональных фенотипах ХОБЛ.</p><p>Обследовано 83 пациента с ХОБЛ разной степени тяжести стабильного течения и 22 практически здоровых добровольцев. После определения фенотипа ХОБЛ по клинико-функциональным признакам пациенты распределены по группам: 38 чел. с бронхитическим и 45 пациентов с эмфизематозным фенотипом. Проводилось клинико-функциональное и лабораторное исследование. Исследовали статические легочные объемы и емкости: функциональная остаточная емкость, остаточный объем легких, общая емкость легких, бронхиальное сопротивление на вдохе и выдохе для определения фенотипа заболевания. Субпопуляции Th1- и Th17-лимфоцитов оценивали по уровню цитокинов в сыворотке крови, туморнекротизирующий фактор (TNFá) интерлейкинов (IL) IL-4, IL-10, IL-17А, IFNã.</p><p>У больных ХОБЛ выявлены особенности иммунного ответа при бронхитическом и эмфизематозном фенотипах. Активация воспалительного процесса с дифференцировкой наивных Т-лимфоцитов по Th1-зависимому пути установлена в 68% случаев при бронхитическом и в 16% случаев при эмфизематозном фенотипах. У пациентов статистически значимо увеличен уровень TNFá, IFNã на фоне снижения IL-4 по сравнению с контролем. Развитие иммунного ответа по Th17-типу установлено в 32% случаев при бронхитическом и 84% случаев при эмфизематозном фенотипах. Его развитие ассоциировалось с увеличением уровня IL-17А, IL-10 и снижением IFNã/IL-17А по сравнению с контролем. Показано, что при бронхитическом фенотипе на ранних стадиях заболевания преобладает дифференцировка Т-хелперов по Th1-пути иммунного ответа. С возрастанием степени тяжести преобладает Th17-тип иммунного ответа. При эмфизематозном фенотипе ХОБЛ иммунный ответ по Th17-пути формируется на ранних стадиях заболевания. Выявлены взаимосвязи между показателями системного воспаления и параметрами функции внешнего дыхания. Показана обратная зависимость между TNFá и соотношением ООЛ/ОЕЛ при Th1-типе иммунного ответа. Установлена прямая корреляция между уровнем IL-17А и параметрами функции внешнего дыхания (ОФВ1, ОФВ1/ФЖЕЛ), а также между IFNã/IL-17А и ФОЕ при Th17-типе иммунного ответа.</p></abstract><trans-abstract xml:lang="en"><p>Chronic obstructive pulmonary disease (COPD) is considered a heterogeneous disorder exhibiting different phenotypes. Chronic systemic inflammation is an important link in the COPD pathogenesis. The studies of immune response in the context of clinical and functional phenotypes seems relevant. Objective of our work was to study the features of immune response in clinical and functional phenotypes of COPD.</p><p>Eighty-three COPD patients of different severity grade and 22 apparently healthy volunteers were examined. After determining the COPD phenotype by clinical and functional signs, the patients were divided in two groups, i.e., 38 subjects with bronchitis, and 45 patients with emphysematous phenotype. Clinical, functional and laboratory research was carried out in standard mode. Static lung volumes and respiratory capacities were investigated, i.e., functional residual capacity, residual lung volume, total lung capacity, bronchial resistance on inspiration and expiration to assess phenotype of the disease. Subpopulations of Th1 and Th17 lymphocytes were determined by the level of blood serum cytokines, tumor necrosis factor (TNFá), interleukins (IL) IL-4, IL-10, IL-17A, IFNã).</p><p>Different features of immune response were revealed in bronchitic and emphysematous phenotypes of the COPD patients. Activation of inflammatory process with differentiation of naive T lymphocytes along the Th1-dependent pathway was found in 68% of cases with bronchitis and 16% of patients with emphysematous phenotypes. As compared with control group, the patients showed a statistically significant increase in the level of TNFá, IFNã, along with decrease in IL-4. Development of immune response by the Th17 type was found in 32% of cases with bronchitis, and 84% of cases with emphysematous phenotypes. Its emergence was associated with increased IL-17A and IL-10 levels, and a decrease in IFNã/IL-17A compared to the control. Differentiation of T helper cells towards Th1 pathway of immune response has been shown to predominate in bronchitic phenotype and at early stages of the disease. The Th17 type of immune response prevailed with increasing severity of the disorder. In emphysematous phenotype of COPD, the Th17-pathway of immune response develops at early stages of the disease. Some relationships are revealed between the systemic inflammation indexes and functional parameters of external respiration. An inverse relationship between TNFá and the OOL/OEL ratio in Th1 type of immune response has been shown. A direct correlation was found between the level of IL-17A and the parameters of external respiration function (FEV1, FEV1/FVC), as well as between IFNã/IL-17A and functional residual capacity in Th17 type of immune response.</p><p>The type of immune response is associated with severity of the disease, as well with clinical and functional phenotype of COPD. Progression of the disease, broncho-obstructive disorders and hyperinflation are associated with increased levels of cytokines that provide cell polarization along the Th17 pathway. Determination of COPD phenotype and the type of immune response already at an early stage of the disease will enable prediction of its course and justify the choice of phenotype-oriented therapy.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>хроническая обструктивная болезнь легких</kwd><kwd>клинические фенотипы</kwd><kwd>Тh-зависимый тип иммунного ответа</kwd></kwd-group><kwd-group xml:lang="en"><kwd>chronic obstructive pulmonary disease</kwd><kwd>clinical phenotypes</kwd><kwd>Th-dependent type immune response</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Антонюк М.В., Новгородцева Т.П., Юренко А.В., Минеева Е.Е., Кнышова В.В. Оценка риска развития обострений у пациентов с хронической обструктивной болезнью легких // Здоровье. Медицинская экология. Наука, 2017. Т. 71, № 4. С. 11-15.</mixed-citation><mixed-citation xml:lang="en">Antonyuk M.V., Novgorodtseva T.P., Yurenko A.V., Mineeva E.E., Knyshova V.V. Estimation of risk of exacerbations in patients with chronic obstructive pulmonary disease. Zdorovye. Meditsinskaya ekologiya. Nauka = Health. Medical Ecology. Science, 2017, Vol. 71, no. 4, pp. 11-15. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Бережная Н.М., Сепиашвили Р.И. Интерлейкины в патогенезе атопических аллергических заболеваний // Аллергология и иммунология, 2014. T. 15, № 3. С. 169-176.</mixed-citation><mixed-citation xml:lang="en">Berezhnaya N.M., Sepiashvili R.I. Interleukins in the pathogenesis of atopic allergic diseases. Allergologiya i immunologiya = Allergology and Immunology, 2014, Vol. 15, no. 3, pp. 169-176. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Долинина Л.Ю., Делиева А.Н., Богданова Е.О., Галкина О.В., Трофимов В.И. Особенности локального воспаления при хронической обструктивной болезни легких в зависимости от степени тяжести // Медицинская иммунология, 2013. T. 15, № 2. С. 141-146. doi: 10.15789/1563-0625-2013-2-141-146.</mixed-citation><mixed-citation xml:lang="en">Dolinina L.Yu., Delieva A.N., Bogdanova E.O., Galkina O.V., Troﬁmov V.I. Features of local inﬂammation in chronic obstructive pulmonary disease, depending on the severity. Meditsinskaya immunologiya = Medical Immunology (Russia). 2013, Vol. 15, no. 2, pp. 141-146. (In Russ.) doi: 10.15789/1563-0625-2013-2-141-146.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Калинина Е.П., Виткина Т.И., Кнышова В.В., Федосеева Е.А., Новгородцева Т.П., Гвозденко Т.А. Клинико-иммунологическое сопоставление при Th-зависимых механизмах иммунного ответа у больных хронической обструктивной болезнью легких // Медицинская иммунология, 2018. T. 20, № 6. С. 855- 864. doi: 10.15789/1563-0625-2018-6-855-864.</mixed-citation><mixed-citation xml:lang="en">Kalinina E.P., Vitkina T.I., Knyshova V.V., Fedoseeva E.A., Novgorodtseva T.P., Gvozdenko T.A. Clinical and immunological comparison in Th-dependent mechanisms of the immune response in patients with chronic obstructive pulmonary disease. Meditsinskaya immunologiya = Medical Immunology (Russia), 2018, Vol. 20, no. 6, pp. 855-864. (In Russ.) doi: 10.15789/1563-0625-2018-6-855-864.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Калинина Е.П., Лобанова Е.Г., Антонюк М.В. Иммунометаболические фенотипы хронической обструктивной болезни легких у мужчин // Медицинская иммунология, 2014. T. 16, № 4. С. 375-380. doi: 10.15789/1563-0625-2014-4-375-380.</mixed-citation><mixed-citation xml:lang="en">Kalinina E.P., Lobanova E.G., Antonyuk M.V. Immune and metabolic phenotypes of chronic obstructive pulmonary disease in men. Meditsinskaya immunologiya = Medical Immunology (Russia), 2014, Vol. 16, no. 4, pp. 375-380. (In Russ.) doi: 10.15789/1563-0625-2014-4-375-380.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Коровкина Е.С., Костинов М.П. Иммунопатологические механизмы внебольничной пневмонии и хронической обструктивной болезни легких, обусловленные инфекционной этиологией этих заболеваний, и пути возможной иммунокоррекции // Журнал микробиологии, эпидемиологии и иммунобиологии, 2019. № 2. С. 100-109.</mixed-citation><mixed-citation xml:lang="en">Korovkina E.S., Kostinov M.P. Immunopathological mechanisms of community-acquired pneumonia and chronic obstructive pulmonary disease caused by the infectious etiology of these diseases, and the ways of possible immunocorrection. Zhurnal mikrobiologii, epidemiologii i immunologii = Journal of Microbiology, Epidemiology and Immunobiology, 2019, no. 2, pp. 100-109. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Лобанова Е.Г., Калинина Е.П., Денисенко Ю.К. Особенности содержания цитокинов Th1- и Th17-лимфоцитов у лиц с хронической обструктивной болезнью легких // Медицинская иммунология, 2016. T. 18, № 3. С. 287-290. doi: 10.15789/1563-0625-2016-3-287-290.</mixed-citation><mixed-citation xml:lang="en">Lobanova E.G., Kalinina E.P., Denisenko Yu.K. Peculiarities of the cytokine levels of Th1 and Th17 lymphocytes in patients with chronic obstructive pulmonary disease. Meditsinskaya immunologiya = Medical Immunology (Russia), 2016, Vol. 18, no. 3, pp. 287-290. (In Russ.) doi: 10.15789/1563-0625-2016-3-287-290.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Малыхин Ф.Т., Косторная И.В. Морфологические изменения органов дыхания при хронической обструктивной болезни легких // Архив патологии, 2016. № 1. С. 42-50.</mixed-citation><mixed-citation xml:lang="en">Malykhin F.T., Kostornaya I.V. Morphological changes in the respiratory system in chronic obstructive pulmonary disease. Arkhiv patologii = Archives of Pathology, 2016, no. 1, pp. 42-50. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Никонова А.А., Хаитов М.Р., Хаитов Р.М. Характеристика и роль различных популяций макрофагов в патогенезе острых и хронических заболеваний легких // Медицинская иммунология, 2017. T. 19, № 6. С. 657-672. doi: 10.15789/1563-0625-2017-6-657-672.</mixed-citation><mixed-citation xml:lang="en">Nikonova A.A., Khaitov M.R., Khaitov R.M. Characteristics and role of diﬀerent populations of macrophages in the pathogenesis of acute and chronic lung diseases. Meditsinskaya immunologiya = Medical Immunology (Russia), 2017, Vol. 19, no. 6, pp. 657-672. (In Russ.) doi: 10.15789/1563-0625-2017-6-657-672.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Новиков Д.К., Смирнова О.В. Иммунологические фенотипы хронической обструктивной болезни легких: перспективы иммунокоррекции // Вестник ВГМУ, 2014. T. 13, № 4. С. 102-109.</mixed-citation><mixed-citation xml:lang="en">Novikov D.K., Smirnova O.V. Immunological phenotypes of chronic obstructive pulmonary disease: prospects for immune. Vestnik VGMU = Bulletin of Vitebsk State Medical University. 2014, Vol. 13, no. 4, pp. 102-109. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Трофименко И.Н., Черняк Б.А. Сравнительная клинико-функциональная характеристика бронхитического и эмфизематозного фенотипов хронической обструктивной болезни легких // Сибирский медицинский журнал, 2011. № 6. С. 59-63.</mixed-citation><mixed-citation xml:lang="en">Troﬁmenko I.N., Chernyak B.A. Comparative clinical and functional characteristics of bronchitic and emphysematous phenotypes of chronic obstructive pulmonary disease. Sibirskiy meditsinskiy zhurnal = Siberian Medical Journal, 2011, no. 6, pp. 59-63. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Шестовицкий В.А., Гринштейн Ю.И., Максимова А.В. Цитооксидантные характеристики местного фагоцитарноклеточного иммунитета в стадии тяжелого обострения при клинических фенотипах хронической обструктивной болезни легких // Пульмонология, 2017. T. 27, № 4. С. 478-483.</mixed-citation><mixed-citation xml:lang="en">Shestovitsky V.A., Grinshtein Yu.I., Maksimova A.V. Cytooxidant characteristics of local phagocytic cell immunity in the stage of severe exacerbation in clinical phenotypes of chronic obstructive pulmonary disease. Pulmonologiya = Pulmonology, 2017, Vol. 27, no. 4, pp. 478-483. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Antoniu S.A. Targeting the TNF-alpha pathway in sarcoidosis. Expert Opin. Ther. Targets, 2010, Vol. 14, no 1, pp. 21-29.</mixed-citation><mixed-citation xml:lang="en">Antoniu S.A. Targeting the TNF-alpha pathway in sarcoidosis. Expert Opin. Ther. Targets, 2010, Vol. 14, no 1, pp. 21-29.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Arkhipov V., Arkhipova D., Miravitlles M., Lazarev A., Stukalina E. Characteristics of COPD patients according to GOLD classiﬁcation and clinical phenotypes in the Russian Federation: the SUPPORT trial. Int. J. Chron. Obstruct. Pulmon. Dis., 2017, Vol. 12, pp. 3255-3262.</mixed-citation><mixed-citation xml:lang="en">Arkhipov V., Arkhipova D., Miravitlles M., Lazarev A., Stukalina E. Characteristics of COPD patients according to GOLD classiﬁcation and clinical phenotypes in the Russian Federation: the SUPPORT trial. Int. J. Chron. Obstruct. Pulmon. Dis., 2017, Vol. 12, pp. 3255-3262.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Bade G., Khan M.A., Srivastava A.K., Khare P., Solaiappan K.K., Guleria R., Palaniyar N., Talwar A. Serum cytokine proﬁling and enrichment analysis reveal the involvement of immunological and inﬂammatory pathways in stable patients with chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis., 2014, Vol. 9, no. 1, pp. 759-773.</mixed-citation><mixed-citation xml:lang="en">Bade G., Khan M.A., Srivastava A.K., Khare P., Solaiappan K.K., Guleria R., Palaniyar N., Talwar A. Serum cytokine proﬁling and enrichment analysis reveal the involvement of immunological and inﬂammatory pathways in stable patients with chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis., 2014, Vol. 9, no. 1, pp. 759-773.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Burrows B., Fletcher C.M., Heard B.E., Jones N.L., Wootliﬀ J.S. The emphysematous and bronchial types of chronic airways obstruction. A clinicopathological study of patients in London and Chicago. Lancet, 1966, Vol. 287, no. 7442, pp. 830-835.</mixed-citation><mixed-citation xml:lang="en">Burrows B., Fletcher C.M., Heard B.E., Jones N.L., Wootliﬀ J.S. The emphysematous and bronchial types of chronic airways obstruction. A clinicopathological study of patients in London and Chicago. Lancet, 1966, Vol. 287, no. 7442, pp. 830-835.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Caramori G., Casolari P., Barczyk A., Durham A, Stefano A., Adcock Ia. COPD immunopathology. Semin. Immunopathol., 2014, Vol. 38, no. 4, pp. 497-515.</mixed-citation><mixed-citation xml:lang="en">Caramori G., Casolari P., Barczyk A., Durham A, Stefano A., Adcock Ia. COPD immunopathology. Semin. Immunopathol., 2014, Vol. 38, no. 4, pp. 497-515.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Cruz T., López-Giraldo A., Noell G., Casas-Recasens S., Garcia T., Molins L., Juan M., Fernandez M.A., Agustí A., Faner R. Multi-level immune response network in mild-moderate Chronic Obstructive Pulmonary Disease (COPD). Respir. Res., 2019, Vol. 20, 152. doi: 10.1186/s12931-019-1105-z.</mixed-citation><mixed-citation xml:lang="en">Cruz T., López-Giraldo A., Noell G., Casas-Recasens S., Garcia T., Molins L., Juan M., Fernandez M.A., Agustí A., Faner R. Multi-level immune response network in mild-moderate Chronic Obstructive Pulmonary Disease (COPD). Respir. Res., 2019, Vol. 20, 152. doi: 10.1186/s12931-019-1105-z.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Eltboli O., Bafadhel M., Hollins F., Wright A., Hargadon B., Kulkarni N., Brightling C. COPD exacerbation severity and frequency is associated with impaired macrophage eﬀerocytosis of eosinophils. BMC Pulm. Med., 2014, Vol. 14, 112. doi: 10.1186/1471-2466-14-112.</mixed-citation><mixed-citation xml:lang="en">Eltboli O., Bafadhel M., Hollins F., Wright A., Hargadon B., Kulkarni N., Brightling C. COPD exacerbation severity and frequency is associated with impaired macrophage eﬀerocytosis of eosinophils. BMC Pulm. Med., 2014, Vol. 14, 112. doi: 10.1186/1471-2466-14-112.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Fraig M., Shreesha U., Savici D., Katzenstein A.L. Respiratory bronchiolitis: a clinicopathologic study in current smokers, ex-smokers, and never-smokers. Am. J. Surg. Pathol., 2002, Vol. 26, no. 5, pp. 647-653.</mixed-citation><mixed-citation xml:lang="en">Fraig M., Shreesha U., Savici D., Katzenstein A.L. Respiratory bronchiolitis: a clinicopathologic study in current smokers, ex-smokers, and never-smokers. Am. J. Surg. Pathol., 2002, Vol. 26, no. 5, pp. 647-653.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Ivanov S., Linden A. New drugs and targets for asthma and COPD. Progr. Respir. Res., 2010, no. 39, pp. 3-23.</mixed-citation><mixed-citation xml:lang="en">Ivanov S., Linden A. New drugs and targets for asthma and COPD. Progr. Respir. Res., 2010, no. 39, pp. 3-23.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Koenderman L., Chilvers E. Future treatment in patients with chronic obstructive pulmonary disease: To reverse or not to reverse steroid resistance – that is the question. J. Allergy Clin. Immunol., 2014, Vol. 134, no. 2, pp. 314-322.</mixed-citation><mixed-citation xml:lang="en">Koenderman L., Chilvers E. Future treatment in patients with chronic obstructive pulmonary disease: To reverse or not to reverse steroid resistance – that is the question. J. Allergy Clin. Immunol., 2014, Vol. 134, no. 2, pp. 314-322.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Le O., Pichavant R.M., Frealle E., Guillon A., Si-Tahar M., Gosset Ph., Th17 cytokines: novel potential therapeutic targets for COPD pathogenesis and exacerbations. Eur. Respir. J., 2017, Vol. 50, no. 4, 1602434. doi: 10.1183/13993003.02434-2016.</mixed-citation><mixed-citation xml:lang="en">Le O., Pichavant R.M., Frealle E., Guillon A., Si-Tahar M., Gosset Ph., Th17 cytokines: novel potential therapeutic targets for COPD pathogenesis and exacerbations. Eur. Respir. J., 2017, Vol. 50, no. 4, 1602434. doi: 10.1183/13993003.02434-2016.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Li X.N., Pan X., Qiu D. Imbalances of Th17 and Treg cells and their respective cytokines in COPD patients by disease stage. Int. J. Clin. Exp. Med., 2014, Vol. 12, no. 7, pp. 5324-5329.</mixed-citation><mixed-citation xml:lang="en">Li X.N., Pan X., Qiu D. Imbalances of Th17 and Treg cells and their respective cytokines in COPD patients by disease stage. Int. J. Clin. Exp. Med., 2014, Vol. 12, no. 7, pp. 5324-5329.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Ponce-Gallegos M.A., Ramírez-Venegas A., Falfán-Valencia R. Th17 proﬁle in COPD exacerbations. Int. J. Chron. Obstruct. Pulmon. Dis., 2017, Vol. 12, pp. 1857-1865.</mixed-citation><mixed-citation xml:lang="en">Ponce-Gallegos M.A., Ramírez-Venegas A., Falfán-Valencia R. Th17 proﬁle in COPD exacerbations. Int. J. Chron. Obstruct. Pulmon. Dis., 2017, Vol. 12, pp. 1857-1865.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Pridgeon С., Bugeon L., Donnelly L., Straschil U., Tudhope S.J., Fenwick P., Lamb J.R., Barnes P.J., Dallman M.J. Regulation of IL-17 in chronic inﬂammation in the human lung. Clin. Sci., 2011, Vol. 120, no. 12, pp. 515-524.</mixed-citation><mixed-citation xml:lang="en">Pridgeon С., Bugeon L., Donnelly L., Straschil U., Tudhope S.J., Fenwick P., Lamb J.R., Barnes P.J., Dallman M.J. Regulation of IL-17 in chronic inﬂammation in the human lung. Clin. Sci., 2011, Vol. 120, no. 12, pp. 515-524.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Snoeck-Stroband J.B., Lapperre T.S., Gosman M.M.E., Boezen H.M., Timens W., ten Hacken N.H.T., Sont J.K., Sterk P.J., Hiemstra P.S.; Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease (GLUCOLD) Study Group. Chronic bronchitis sub-phenotype within COPD: inﬂammation in sputum and biopsies. Eur. Respir. J., 2008, Vol. 31, pp. 70-77.</mixed-citation><mixed-citation xml:lang="en">Snoeck-Stroband J.B., Lapperre T.S., Gosman M.M.E., Boezen H.M., Timens W., ten Hacken N.H.T., Sont J.K., Sterk P.J., Hiemstra P.S.; Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease (GLUCOLD) Study Group. Chronic bronchitis sub-phenotype within COPD: inﬂammation in sputum and biopsies. Eur. Respir. J., 2008, Vol. 31, pp. 70-77.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Wang H., Ying H., Wang S. Imbalance of peripheral blood Th17 and Treg responses in patients with chronic obstructive pulmonary disease. Clin. Respir. J., 2015, Vol. 9, no. 3, pp. 330-341.</mixed-citation><mixed-citation xml:lang="en">Wang H., Ying H., Wang S. Imbalance of peripheral blood Th17 and Treg responses in patients with chronic obstructive pulmonary disease. Clin. Respir. J., 2015, Vol. 9, no. 3, pp. 330-341.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
